Definition

A preparation of universal T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, BCMA-specific universal CAR-expressing T lymphocytes LCAR-BCX are directed to cells expressing BCMA and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is overexpressed on malignant plasma cells.